FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280629396> ?p ?o ?g. }

• W4280629396 abstract "Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear.We analyzed data of 160 consecutive patients with residual TNBC from eight cancer-center. Pathologic response was defined into two groups as having good-pathologic-response (MillerPayneGrading (MPG) IV-III) or poor-pathologic-response (MPG I-II). The characteristics of patients were compared regarding adjuvant capecitabine usage.Univariate-analysis revealed that age, histology, clinical-stage, tumor-size, lymph-nodes number, menopausal status, and pathological-stage were significantly different between two groups. In multivariate-analysis, menopausal status (p = 0.043) and residual tumor-size (p < 0.001) were found to be independent prognostic factors for pathological response. The hazard-ratio for disease recurrence and death in the poor-response group with adjuvant capecitabine was 2.94 (95% confidence-interval (CI), 1.21 to 7.10; p = 0.016) and 4.080 (95% CI, 1.22 to 13.64; p = 0.022), respectively. DFS (p = 0.58) and OS (p = 0.89) improvements with adjuvant capecitabine were not demonstrated in good-response groups.This multicenter-study suggested that only the poor-response group to NAC achieved benefit from adjuvant capecitabine. Postmenopausal status and residual tumor-size were related to poor prognosis." @default.
• W4280629396 created "2022-05-22" @default.
• W4280629396 creator A5008382382 @default.
• W4280629396 creator A5009017781 @default.
• W4280629396 creator A5017817543 @default.
• W4280629396 creator A5023804283 @default.
• W4280629396 creator A5024984311 @default.
• W4280629396 creator A5029566579 @default.
• W4280629396 creator A5030410773 @default.
• W4280629396 creator A5054602049 @default.
• W4280629396 creator A5061724506 @default.
• W4280629396 creator A5077360580 @default.
• W4280629396 creator A5083552699 @default.
• W4280629396 creator A5087558124 @default.
• W4280629396 date "2022-05-11" @default.
• W4280629396 modified "2023-10-18" @default.
• W4280629396 title "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?" @default.
• W4280629396 cites W2050761481 @default.
• W4280629396 cites W2071204159 @default.
• W4280629396 cites W2075894019 @default.
• W4280629396 cites W2094599068 @default.
• W4280629396 cites W2096145980 @default.
• W4280629396 cites W2124623816 @default.
• W4280629396 cites W2147415463 @default.
• W4280629396 cites W2152793272 @default.
• W4280629396 cites W2590177834 @default.
• W4280629396 cites W2618058692 @default.
• W4280629396 cites W2806074020 @default.
• W4280629396 cites W2950255470 @default.
• W4280629396 cites W2963709818 @default.
• W4280629396 cites W2966744080 @default.
• W4280629396 cites W2981000034 @default.
• W4280629396 cites W3015248490 @default.
• W4280629396 cites W3037385414 @default.
• W4280629396 cites W3165271511 @default.
• W4280629396 doi "https://doi.org/10.1080/14737140.2022.2076670" @default.
• W4280629396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35543015" @default.
• W4280629396 hasPublicationYear "2022" @default.
• W4280629396 type Work @default.
• W4280629396 citedByCount "0" @default.
• W4280629396 crossrefType "journal-article" @default.
• W4280629396 hasAuthorship W4280629396A5008382382 @default.
• W4280629396 hasAuthorship W4280629396A5009017781 @default.
• W4280629396 hasAuthorship W4280629396A5017817543 @default.
• W4280629396 hasAuthorship W4280629396A5023804283 @default.
• W4280629396 hasAuthorship W4280629396A5024984311 @default.
• W4280629396 hasAuthorship W4280629396A5029566579 @default.
• W4280629396 hasAuthorship W4280629396A5030410773 @default.
• W4280629396 hasAuthorship W4280629396A5054602049 @default.
• W4280629396 hasAuthorship W4280629396A5061724506 @default.
• W4280629396 hasAuthorship W4280629396A5077360580 @default.
• W4280629396 hasAuthorship W4280629396A5083552699 @default.
• W4280629396 hasAuthorship W4280629396A5087558124 @default.
• W4280629396 hasConcept C121608353 @default.
• W4280629396 hasConcept C126322002 @default.
• W4280629396 hasConcept C143998085 @default.
• W4280629396 hasConcept C144301174 @default.
• W4280629396 hasConcept C146357865 @default.
• W4280629396 hasConcept C151730666 @default.
• W4280629396 hasConcept C207103383 @default.
• W4280629396 hasConcept C2776694085 @default.
• W4280629396 hasConcept C2777863537 @default.
• W4280629396 hasConcept C2777909004 @default.
• W4280629396 hasConcept C2777982462 @default.
• W4280629396 hasConcept C2780110267 @default.
• W4280629396 hasConcept C38180746 @default.
• W4280629396 hasConcept C44249647 @default.
• W4280629396 hasConcept C526805850 @default.
• W4280629396 hasConcept C530470458 @default.
• W4280629396 hasConcept C71924100 @default.
• W4280629396 hasConcept C86803240 @default.
• W4280629396 hasConcept C90924648 @default.
• W4280629396 hasConceptScore W4280629396C121608353 @default.
• W4280629396 hasConceptScore W4280629396C126322002 @default.
• W4280629396 hasConceptScore W4280629396C143998085 @default.
• W4280629396 hasConceptScore W4280629396C144301174 @default.
• W4280629396 hasConceptScore W4280629396C146357865 @default.
• W4280629396 hasConceptScore W4280629396C151730666 @default.
• W4280629396 hasConceptScore W4280629396C207103383 @default.
• W4280629396 hasConceptScore W4280629396C2776694085 @default.
• W4280629396 hasConceptScore W4280629396C2777863537 @default.
• W4280629396 hasConceptScore W4280629396C2777909004 @default.
• W4280629396 hasConceptScore W4280629396C2777982462 @default.
• W4280629396 hasConceptScore W4280629396C2780110267 @default.
• W4280629396 hasConceptScore W4280629396C38180746 @default.
• W4280629396 hasConceptScore W4280629396C44249647 @default.
• W4280629396 hasConceptScore W4280629396C526805850 @default.
• W4280629396 hasConceptScore W4280629396C530470458 @default.
• W4280629396 hasConceptScore W4280629396C71924100 @default.
• W4280629396 hasConceptScore W4280629396C86803240 @default.
• W4280629396 hasConceptScore W4280629396C90924648 @default.
• W4280629396 hasLocation W42806293961 @default.
• W4280629396 hasLocation W42806293962 @default.
• W4280629396 hasOpenAccess W4280629396 @default.
• W4280629396 hasPrimaryLocation W42806293961 @default.
• W4280629396 hasRelatedWork W2338961863 @default.
• W4280629396 hasRelatedWork W2534174115 @default.
• W4280629396 hasRelatedWork W2623400261 @default.
• W4280629396 hasRelatedWork W2652729657 @default.
• W4280629396 hasRelatedWork W2770409748 @default.

• next